| Biomarker ID | 786 |
| PMID | 22009027 |
| Year | 2011 |
| Biomarker | AMACR+CSTA+HPN+MYO6+LAMB3+ABCC4 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated: [ABCC4, AMACR, HPN and MYO6]; Downregulated: [CSTA and LAMB3] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Tumor Vs Normal Tissues |
| Type of Biomarker | Diagnostic |
| Cohort | 38 patients were biopsied for PCA. More samples for validation were further added and the final cohort had 84 samples such that 19 were non-tumoral and 65 were tumoral |
| Senstivity | 88.8% |
| Specificity | 96.1% |
| AUC | NA |
| Accuracy | 92.6% |
| Level Of Significance | p<0.001 |
| Method Used | Quantitative real time PCR (qRT-PCR) |
| Clinical | No |
| Remarks | Gene signature was created from the surplus material washed off from needle biopsies. |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Cohort |
| Technical Name | AMACR, CSTA, HPN, MYO6, LAMB3, ABCC4 |